

ALPIC 2022

**Advanced Learning on Platelets
& Thrombosis International Course**

4-6 November 2022

Kalavrita Canyon Hotel

KALAVRITA-GREECE

Alexandros Tselepis

Professor
of Biochemistry-Clinical
Chemistry, Department
of Chemistry, University
of Ioannina

Course Directors:

John Goudevenos

Emeritus Professor of
Internal Medicine-Cardiology,
Faculty of Medicine,
School of Health Sciences,
University of Ioannina

Haralampos Milonis

Professor of Internal
Medicine, Faculty
of Medicine, School of Health
Sciences, University
of Ioannina

Organizer:



European and Mediterranean League
Against Thrombotic Diseases

The Congress will be accredited
with **21 C.M.E. Credits**
by the Panhellenic Medical Association

Scientific Program

Η ΔΙΚΗ ΣΑΣ ΠΡΟΝΟΗΤΙΚΟΤΗΤΑ ΠΡΟΔΙΑΓΡΑΦΕΙ ΤΟ ΜΕΛΛΟΝ ΤΟΥ



ΣΕ ΠΕΡΙΣΤΑΤΙΚΑ
MBKM[†] ABLATION^{1*} post PCI^{2**}

**Ασθενής με μη βαλβιδική
Κολπική Μαρμαρυγή**

**150
mg**

150 mg BID
Κύρια
δοσολογία

**110
mg**

110 mg BID
Ασθενείς
ηλικίας ≥ 80 ετών
ή συγχρόνηση
με βεραπαμίλη
ή αυξημένος
αιμορραγικός κίνδυνος

Pradaxa®
dabigatran etexilate

Praxbind®
idarucizumab

Κλείνοντας τον κύκλο

1. Calkins H et al. - NEJM 2017 Apr 27;376:1627-1636. 2. Cannon CP et al NEJM 2017 Oct 19, 377(16):1513-1524.
3. Περίληψη Χαρακτηριστικών Προϊόντος Pradaxa® 4. Περίληψη Χαρακτηριστικών Προϊόντος Praxbind®.

[†] Μη βαλβιδική κολπική μαρμαρυγή.

^{*} RE-CIRCUIT: αξιολόγησε την ασφάλεια της χαρής δισκιοθήρας με dabigatran 150 mg BID σε ασθενείς με ΚΜ που υποβάλλονται σε κατάλυση.

^{**} RE-DUAL PCI αξιολόγησε την ασφάλεια δύο σημείων διπλής θεραπείας με dabigatran 110 mg και 150 mg BID χωρίς ασπρίνη έναντι της καθιερωμένης τριπλής αγωγής με βαρφαρίνη.

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή
με
Ασπρίνη
ΟΛΕΣ τις αντιπηκτικές ενέσεις για
ΟΑΑ τα φάρμακα
Συμπληρώνονται την
«HITRINK KAPTA»

ΚΑΤΟΧΟΣ ΤΗΣ ΔΙΑΔΙΑΚΤΙΚΗΣ ΚΥΚΛΟΦΟΡΙΑΣ: Boehringer Ingelheim International GmbH, Binger Str. 173, 55216 Ingelheim am Rhein, Γερμανία. **ΑΡΙΘΜΟΣ ΕΠΙΔΕΙΞΗΣ:** ΔΑΔΙΑΣ ΚΥΚΛΟΦΟΡΙΑΣ: PRADAXA®: EU/1/08/442/001. PRAXBIND®: EU/1/15/150/001. **ΗΜΕΡΟΜΗΝΙΑ ΠΡΩΤΗΣ ΕΓΓΕΓΓΡΑΦΗΣ ΤΗΣ ΔΑΔΙΑΣ:** PRADAXA®: Ημερομηνία πρώτης έγκρισης: 18 Μαρτίου 2008. Ημερομηνία τελευταίας ανανέωσης: 08 Ιανουαρίου 2018. PRAXBIND®: Ημερομηνία πρώτης έγκρισης: 20 Νοεμβρίου 2015. Ημερομηνία τελευταίας ανανέωσης: 17 Σεπτεμβρίου 2020. **ΗΜΕΡΟΜΗΝΙΑ ΑΝΑΒΕΒΡΗΣΗΣ ΤΟΥ ΚΕΙΜΕΝΟΥ:** PRADAXA®: 20/01/2022. PRAXBIND®: 17/09/2022. **PRADAXA CAPS 110 MG/CAP ΒΤ460 (σε BLISTERS/ALU/ALU):** 45,45 €, Α.Τ. 66,45 €. **PRADAXA CAPS 150 MG/CAP 1 Φιάλη (PP) x 60/ΑΤ:** 45,45 €, Α.Τ. 65,45 €. **PRADAXA CAPS 150MG/CAP ΒΤ460 (σε BLISTERS/ALU/ALU):** 60/ΑΤ: 46,27 €, Α.Τ. 67,65 €. **PRADAXA CAPS 150MG/CAP 1 Φιάλη (PP) x 60/ΑΤ:** 46,27 €, Α.Τ. 67,65 €. **PRADAXA CAPS 75MG/CAP ΒΤ460 (σε BLISTERS/ALU/ALU):** 60/ΑΤ: 46,27 €, Α.Τ. 67,65 €. **Praxbind 2,5 g/50 mL, Blisters:** 2.230,37 €, Α.Τ. 2.701,83 €. **Χορηγούνται με ισχυρή ουσιώδη.**



WELCOME MESSAGE

Dear Colleagues,

We are pleased to welcome you to **ALPIC 2022** (Advanced Learning on Platelets & Thrombosis International Course), the 12th international scientific event on Platelets and Thrombosis, taking place this year in **Kalavrita**, Peloponnese, Greece, at Kalavrita Canyon Hotel, on **4-6 November, 2022**. ALPIC 2022 is organized by the European and Mediterranean League against Thrombotic Diseases (EMLTD), having as Course Directors Professors A. Tselepis, I. Goudevenos and H. Milionis. The Course aims to serve as a knowledge transfer forum for scientists in the current aspects of Platelet and Thrombosis research, ranging from the basic science to the clinical practice. The scientific program is designed to highlight the rapid development and ongoing evolution on the mechanisms underlying Thrombosis and Haemostasis along with discussion regarding all current advances in Antiplatelet and Anticoagulant therapy. We are proud that ALPIC has gained worldwide warm acceptance and recognition for its scientific merit and we do hope that ALPIC 2022 will further strengthen the European and Mediterranean network for Thrombosis in both basic research and clinical practice. ALPIC 2022 is organized with the contribution of our hosting partners, the Atherothrombosis Research Centre of the University of Ioannina and the Institute for the Study and Education on Thrombosis and Antithrombotic Therapy, which will give us the opportunity to bring together scientists and experts having a wide spectrum of disciplines, who will share current knowledge on various aspects of Thrombosis. The course local organizing committee consisted of University Professors with different specialties has created an attractive and comprehensive scientific programme with care and appreciation for attendees' scientific and personal enjoyment. An internationally recognized panel of invited speakers will present state of the art lectures and will create an excellent opportunity for all participants to stimulate an extended and very constructive discussion both inside and outside the lecture hall.

The dreamy setting with picturesque squares, stone-paved streets and cute little houses of Kalavrita will welcome ALPIC 2022. Kalavrita is a town, a province and a municipality in the East Central part of the prefecture of Achaia. The historic town of Kalavrita, one of the most exciting destinations of Peloponnese, will add to the scientific quality of the presentations, making this event a remarkable one for all participants. The Organizers will spare no efforts to ensure that ALPIC 2022 will be an exciting and enriching experience for all participants. We welcome you and we wish you all enjoy ALPIC 2022 in the picturesque landscape offered by Kalavrita and its mountainous landscape.

With our best regards,

The ALPIC 2022 Course Directors

Prof. Alexandros Tselepis Prof. Ioannis Goudevenos Prof. Haralampos Milionis

ALPIC ORGANIZER

■ Organizer:



European and Mediterranean League
Against Thrombotic Diseases

■ Course Directors:

Alexandros Tselepis

Professor of Biochemistry
- Clinical Chemistry
Department of Chemistry,
University of Ioannina

John Goudevenos

Emeritus Professor
of Internal Medicine
Cardiology, Faculty of
Medicine, School of
Health Sciences
University of Ioannina

Haralampos Milionis

Professor of Internal
Medicine, Faculty
of Medicine, School
of Health Sciences,
University of Ioannina

Here's why! See you in Kalavrita for what promises to be a most exciting congress!

The ALPIC 2022 scientific program is focused on realistic views of controversial issues in thrombosis and antithrombotic therapy. Sessions include a combination of Keynote lectures, Clinical Seminars Plenary Sessions, Debates, Meet the Experts Sessions presented by a faculty of internationally renowned leaders.

Friday, November 4th, 2022

11.00 **Registrations**

11.30-13.30 **The Most Impactful Antithrombotic Trials in 2021-2022**

Chairs: Stratis **Pattakos**, Dimitrios **Alexopoulos**

HEP-COVID

Matilda **Florentin**

MICHELLE, Μελέτη INVICTUS

Theodora **Babali**

REMAP-CAP, ACTIV-4a, and ATTACC

Georgia **Kaiafa**

MASTER DAPT

Dimitrios **Nikas**

ADAPT-TAVR

Georgios **Almpanis**

STOPDAPT-2 ACS

Dimitrios **Alexopoulos**

IMPROVE VTE (Hospitalized medically ill patients)

Ioannis **Koulas**

PACIFIC Program (AF, AMI, STROKE)

John **Goudevenos**

SCIENTIFIC PROGRAMME

Friday, November 4th, 2022

13.30-14.30 **Meet the Experts: From ACS to chronic coronary artery disease. The transition period**

Chairs: Georgios **Kochiadakis**, Dimitrios **Alexopoulos**

P2Y12 Monotherapy following PCI. An alternative approach
Dimitrios **Alexopoulos**

Dual anti platelet therapy duration? Very short or very long?
John **Kanakakis**

Very low dose of rivaroxaban. It is time for a new era
in antithrombotic treatment?
Christos **Katsouras**

The bleeding risk. The true game changer?
Georgios **Almpanis**

14.30-15.30 **Break**

15.30-16.30 **Interactive Workshop. Real-World Data on Thrombosis Incidence and Treatment in Countries Affiliated to EMLTD**

Chairs: Vittorio **Pengo** (Italy), Alexandros **Tselepis**

Croatia: Ana **Bronic**

Greece: Dimitrios **Alexopoulos**

Israel: David **Varon**

Portugal: Joao **Morais**

France: Ismail **Elalamy**

Slovenia: Matija **Kozak**

Spain: Lina **Badimon**

16.30-17.00 **Antithrombotic Therapy in cardiac Operations**

Chair: John **Goudevenos**

Antithrombotic therapy of patients undergoing noncardiac
operations according to 2022 ESC guidelines
Michail **Botis**

Antithrombotic Therapy in Patients Undergoing Transcatheter
interventions for Structural Heart Disease
Gregoris **Pattakos**

Friday, November 4th, 2022

17.00-17.30 **Coffee Break**

17.30-19.00 Plenary Session. Stroke therapeutics: an update

Chairs: Georgios **Tsivgoulis**, John **Ellul**

Tenecteplase vs alteplase for iv thrombolysis in Acute Ischemic Stroke
Georgios **Tsivgoulis**

Safety and efficacy of iv thrombolysis in COVID-19 era
Eleni **Bakola**

Combination of antiplatelets and anticoagulants for secondary stroke prevention
Lina **Palaodimou**

Inhibition of factor XI: a new therapeutic horizon for secondary stroke prevention
John **Ellul**

Inflammation: a new therapeutic target for atherothrombotic stroke prevention
Odysseas **Kargiotis**

19.00-20.00 Plenary Session. Cardiovascular complications in cancer patients

Chairs: Nikos **Tsoukalas**, Dimitrios **Alexopoulos**

Evolving data on cardiovascular complications in cancer
Nikos **Tsoukalas**

Venous Thromboembolism and Risk Stratification in Hematological Malignancies
Georgia **Kaiafa**

Cardiotoxicity of Cardiovascular drugs. Focus on antithrombotics
Alexandros **Tselepis**

Optimizing antithrombotic therapy for atrial fibrillation in cancer
Georgios **Andrikopoulos**

SCIENTIFIC PROGRAMME

Friday, November 4th, 2022

20.20-20.45 Official Opening of ALPIC 2022

Chairs: Alexandros **Tselepis**, John **Goudevenos**, Haralampos **Milionis**

Vice Rector of the University of Ioannina
Minas **Paschopoulos**

President of the EMLTD Society
Alexandros **Tselepis**

President of the Hellenic Cardiological Society
John **Kanakakis**

Mayor of Kalavrita
Athanasios **Papadopoulos**

Respected Metropolitan of Kalavrita
Ieronimos

20.45-21.10 Opening Lecture

Chair: Alexandros **Tselepis**

Deep Learning and Artificial Intelligence
Panos **Vardas**

21.30 **Dinner**

Saturday, November 5th, 2022

08.30-10.00 **Atrial fibrillation and the Prothrombotic state:
New insights for 2021-2022**

Chairs: Dimitrios **Richter**, Kostas **Pappas**

Prothrombotic conditions and Stroke

Georgia **Kaiafa**

Stroke risk assessment in AF: Simplicity and practicality matter

Dimitrios **Richter**

Biomarkers for risk stratification in AF

Stylianos **Tzeis**

Bleeding risk assessment: Its appropriate use
and inappropriate mis-use

Vitorio **Pengo**

10.00-10.30 **Coffee Break**

10.30-11.30 **How to Treat Session. Practical Guidance
in Antithrombotic Therapy**

Moderators: John **Goudevenos**, Anastasios **Spanos**

A 35 year-old woman diagnosed with unprovoked DVT.

How far should we extend the antithrombotic treatment?

Kalliroi **Kalantzi**

A 72 year old patient with colonic cancer and pulmonary embolism

Stavroula **Tsiara**

A 70 Years Old Patient with Atrial Fibrillation on DOAC and Melena

Athanasios **Pipilis**

Stroke management in COVID-19 patients in the Internal
Medicine Unit of a Reference Hospital

Christos **Savopoulos**

11.30-12.00 **Satellite Lecture**

(see page 15)

SCIENTIFIC PROGRAMME

Saturday, November 5th, 2022

12.00-13.00 **Meet the Experts session: Unaddressed issues in Thrombosis and Haemostasis**

Chairs: Efrosyni **Nomikou**, Elias **Kyriakou**

Superficial vein thrombosis: Pathophysiology, risk factors and treatment rationale

Fotios **Girtovitis**

Diagnostic and therapeutic approach to a bleeding patient with normal routine coagulation tests

Despina **Adamidou**

13.00-14.30 **Clinical Seminar. Management of acute ischemic stroke**

Chairs: Haralampos **Milionis**, Eleni **Koromboki**

Organize admission and triage

Konstantinos **Vemmos**

Dissolve thrombus. What to expect?

Dimitris **Sagris**

Retrieving emboli. Where do we stand?

Panagiotis **Papanagiotou**

14.30-15.30 **Break**

15.30-17.00 **Meet the Experts. Management of thrombosis at unusual sites. Which antithrombotic and for how long?**

Chairs: James **Douketis**, Athanasios **Giannoukas**

Cerebral sinus thrombosis

Konstantinos **Vemmos**

Splanchnic thrombosis

Georgios **Glantzounis**

Upper extremity thrombosis

Athanasios **Gianoukas**

Discussants: Elissavet **Grouzi**, Konstantinos **Vemmos**,
Evangelos **Dimakakos**

Saturday, November 5th, 2022

17.00-17.30 **Keynote Lecture**

Chair: Alexandros **Tselepis**

Remote monitoring of cardiometabolic disease patients
Apostolos **Pappas**

17.30-18.00 **Coffee Break**

18.00-20.00 **Plenary Session. Cardiometabolic Risk Factors and Thrombosis. From Pathophysiology to Therapy**

A joint session of EMLTD with Hellenic Atherosclerosis Society

Chairs: Alexandros **Tselepis**, Evangelos **Liberopoulos**

Major dietary patterns and atherothrombotic disease;
from epidemiology to clinical practice
Demosthenes **Panagiotakos**

Postprandial dysmetabolism - A daily stressor of platelets?
Tzortzis **Nomikos**

"GLP-1 receptor agonists and stroke primary prevention"
Theodosios **Philippatos**

Metabolic Syndrome – Diabetes Mellitus and the risk of LEAD
Nikolaos **Tentolouris**

Lp(a) and Thromboembolic Risk. Present and future
Alexandros **Tselepis**

Reduction of ischemic events with the use of PCSK9 inhibitors.
Results from recent clinical trials
Evangelos **Liberopoulos**

SCIENTIFIC PROGRAMME

Saturday, November 5th, 2022

20.00-21.00 **Keynote Lectures. Recent guidelines on antithrombotic management**

Chairs: Vittorio **Pengo (Italy)**, Ioanna **Andreadou**

2022 ACCP perioperative antithrombotic management guidelines
James **Douketis**

2002 ISTH COVID anticoagulation guidelines
Alex **Spyropoulos**

Sunday, November 6th, 2022

09.00-11.00 Pathogenesis of ischemic stroke: Heart and Vessels

Chairs: Christos **Savopoulos**, Athanassios **Protogerou**

Hypertension and ischemic stroke: from pathophysiology to effective management

Nikolaos **Kakaletsis**

Lp (a) and stroke: potential relationship, attributable risk and management

Matilda **Florentin**

PFO: to close or not to close?

Paraskevi **Savvari**

CAS vs. CAE: Pros and cons

Dimitrios **Nikas**

Thrombophilia and stroke: an innocent bystander?

Georgia **Kaiafa**

11.00-11.30 **Break**

11.30-13.15 Challenging the risk and management of venous thromboembolism in Women

Chair: Minas **Paschopoulos**, Theodoros **Stefos**

Moderators: George **Farmakides**, Despoina **Adamidou**

Hormonal therapy and risk of thrombosis

Ploutarchos **Tzoulis**

Special issues regarding the Prophylaxis and Therapy of VTE in women of all ages

Eleftheria **Lefkou**

Post-thrombotic syndrome in women

Konstantinos **Konstantinides**

Thrombosis and Placenta

Vasileios **Papadopoulos**

13.15-13.30 **Discussion**

Saturday, November 5th, 2022

11.30-12.00 Satellite Lecture Pfizer



Chair: Dimitrios **Alexopoulos**

PCI/ACS and Atrial Fibrillation - Optimal Antithrombotic treatment

John **Kanakakis**

Theracor®
bisoprolol fumarate

Theracor plus®
bisoprolol fumarate + hydrochlorothiazide

Αλλάζουμε συνήθειες
στη διαχείριση της
Καρδιαγγειακής Νόσου



Pharmaceutical Laboratories S.A.

ΠΕΡΙΛΗΨΗ ΤΩΝ ΧΑΡΑΚΤΗΡΙΣΤΙΚΩΝ ΤΟΥ ΠΡΟΪΟΝΤΟΣ

1. ΟΝΟΜΑΣΙΑ ΤΟΥ ΦΑΡΜΑΚΕΥΤΙΚΟΥ ΠΡΟΪΟΝΤΟΣ: THERACOR 5 mg επικαλυμμένα με λεπτό υμένιο δισκία. THERACOR PLUS (10+25) mg: 1 επικαλυμμένο με λεπτό υμένιο δισκίο περιέχει 10 mg φουμαρικής βισοπρολόλης και 25 mg υδροχλωροθειαζίδης. **2. ΠΟΙΟΤΙΚΗ ΚΑΙ ΠΟΣΙΤΙΚΗ ΣΥΝΘΕΣΗ:** THERACOR: Κάθε δισκίο περιέχει 5 mg φουμαρική βισοπρολόλη. THERACOR PLUS (10+25) mg: 1 επικαλυμμένο με λεπτό υμένιο δισκίο περιέχει 10 mg φουμαρικής βισοπρολόλης και 25 mg υδροχλωροθειαζίδης. **3. ΦΑΡΜΑΚΟΤΕΧΝΙΚΗ ΜΟΡΦΗ:** Επικαλυμμένο με λεπτό υμένιο δισκίο. **4. ΚΛΙΝΙΚΕΣ ΠΛΗΡΟΦΟΡΙΕΣ:** **Θεραπευτικές ενδείξεις:** THERACOR: Θεραπεία χρόνιας σταθερής καρδιακής ανεπάρκειας με μειωμένη συστολική λειτουργία της αριστεράς κοιλίας ως επιπρόσθετη θεραπεία με αναστολείς του μετατρεπτικού ενζύμου της αγγειοτασίνης και διουρητικά, και προαρτηριακή καρδιακή γλυκοσίδες. THERACOR PLUS: Μειώωση της Υπίστασης Δοσολογία και τρόπος χορήγησης: Τα δισκία πρέπει να λαμβάνονται το πρωί και μπορούν να λαμβάνονται με τροφή. THERACOR: Η μέγιστη συνιστώμενη ημερήσια δόση είναι 10 mg βισοπρολόλης. THERACOR PLUS: Συνίσταται η ατομική titolazione της δόσης με την κάθε ουσία ξεχωριστά. **Αντενδείξεις:** Οξεία καρδιακή ανεπάρκεια ή κατά τη διάρκεια επεισοδίων μη αντιρροπούμενης καρδιακής ανεπάρκειας που απαιτούν ενδοφλέβια πρόσοδο θεραπεία. Καρδιογενής καταπληξία (shock). **Ειδικές προειδοποιήσεις και προφυλάξεις κατά τη χρήση:** Πρέπει να χρησιμοποιείται με προσοχή σε: βρογχόσπασμο (βρογχικό άσθμα, αποφρακτική πνευμονοπάθεια). Σαχαρώδη διαβήτης που εμφανίζεται με μεγάλες διακυμάνσεις στις τιμές γλυκόζης αίματος. **Ανεπιθύμητες ενέργειες:** Βρογχόσπασμος, (όλη), κεφαλαλγία, επιδείνωση, καρδιακή ανεπάρκεια, ναυτία, έμετος, διάρροια, δυσκοιλιότητα, εξάνθημα, ορθοστατική υπόταση, μυϊκή αδυναμία, μυϊκές κράμπες.

THERACOR: Α.Τ. 3.35 €. THERACOR PLUS (10 + 25) mg: Α.Τ. 4.62 €.

Βεβαιώστε να γίνουν τα φάρμακα πιο ασφαλή και
Αναφέρετε ΟΠΕΣ ως ανεπιθύμητες ενέργειες για ΟΛΑ τα φάρμακα.
Σημειώνοντας την "ΕΥΡΩΚΑΡΤ".

A

Almpanis Georgios

Interventional Cardiologist at University Hospital of Patrai

Andreadou Ioanna

Professor, Section of Pharmaceutical Chemistry

Adamidou Despina

Consultant Haematologist, Hippokraton General Hospital, Thessaloniki

Alexopoulos Dimitrios

Professor of Cardiology, School of Medicine, National & Kapodistrian University of Athens, Second Department of Cardiology, Athens University General Hospital "ATTIKON"

Andrikopoulos Georgios

Assistant Professor, KTH Royal Institute of Technology

B

Badimon Lina

Professor, Director, Cardiovascular Program-ICCC, Research Institute-Hospital de la Santa Creu i Sant Pau, IIBSant Pau, CiberCV, Barcelona, Spain, Member of the Board of the European Society of Cardiology 2020-2022, President of EMLTD Foundation - European Mediterranean League Against Thrombotic Diseases

Bakola Eleni

Consultant, 2nd Department of Neurology University Hospital "Attikon"

Babali Theodora

Assistant Curator, 2nd Department of Cardiology, Chest and Heart Department, Ioannina University Hospital

Botis Michail

MD, MSc, Cardiology Resident, 251 Hellenic Air Force General Hospital

Bronic Anna

Scientific Research Associate with interests in haemostasis, haematology, and molecular diagnostics. Specialist in medical biochemistry and laboratory medicine at the Department for laboratory diagnostics in traumatology and orthopaedics. Clinical Institute of Chemistry, Medical School University Hospital 'Sestre Milosrdnice', Zagreb, Croatia. Head of Working Group for laboratory coagulation in CSMBLM that include continuous work on the development, improvement, and implementation procedures for laboratory haemostasis.

D

Demir Muzaffer

Professor Doctor » In 2007, Trakya University Faculty of Medicine

Douketis James

Professor, Department of Medicine, McMaster University, Hamilton, Canada

Dimakakos Evangelos

Vascular Internist, Head of Vascular Unit-Training Center of Angiology of UEMS- of 3rd Department of Internal Medicine of University of Athens Public Hospital 'SOTIRIA' Director of Center of Prevention, Diagnosis and Treatment of Lymphedema -Lymphatic Diseases of Metropolitan Hospital Athens, Greece Elected President of International Society of Lymphology President of World Congress of Lymphology ISL 2021 28th World Congress of Lymphology (isl2021lymphology.com) Greek Delegate of UEMS of Angiology / Vascular Medicine Vice President of Scientific Committee of European Society of Lymphology Member of the International- European & Greek Society of Angiology-Lymphology

INDEX / INVITED FACULTY

E

Elalamy Ismail

Professor of Hematology and Director of Hematology Department of Thrombosis Center, CHU Tenon, France

Ellul John

Professor of Neurology, Faculty of Medicine, School of Health Sciences, University of Patras

F

Farmakides George

Professor ob-gyn,mfm, stony brook university,usa, treasurer of hsmfm

Florentin Matilda

Medical doctor, Department of Internal Medicine, Faculty of Medicine, School of health Science, University of Ioannina

G

Girtovitis Fotios

AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece

Gianoukas Athanasios

Professor of Vascular Surgery, Faculty of Medicine, University of Thessaly, Greece.

Glantzounis Georgios

Surgeon, Professor of Surgery-Transplants, Faculty of Medicine, School of Health Sciences, University of Ioannina

Goudevenos John

Emeritus Professor of Cardiology, Faculty of Medicine, School of Health Sciences, University of Ioannina

Grouzi Elissavet

Consultant of Hematology, Head of Transfusion Service and Clinical Haemostasis, "St Savvas" Oncology Hospital, Athens, Greece

I

Ieronimos

Respected Metropolitan of Kalavrita

K

kaiafa Georgia

Assistant Professor, 1st Educational Pathology Clinic, Faculty of Medicine, Aristotle University of Thessaloniki

Kakaletsis Nikolaos

MD, MSc (ESO Stroke Medicine), PhD, Internist, Second Medical Department, Ippokratio General Hospital, Aristotle University of Thessaloniki, Postdoctoral Researcher, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece

Kalantzi Kalliroti

Cardiologist, Dr of University of Ioannina

Kanakakis John

Head of Hemodynamic Department, General Hospital of Athens "Alexandra", President of Hellenic Society of Cardiology

Kargiotis Odyseas

Neurologist - Curator, Metropolitan Hospital Athens

Katsouras Christos

Associate Professor of Cardiology, Faculty of Medicine, School of Health Sciences, University of Ioannina

Kiriakou Elias

Hematologist, Curator of Hematology Laboratory & Blood Donation Service, Athens University General Hospital "ATTIKON"

Kochiadakis Georgios

Dean of Medical School, University of Crete, Professor of Cardiology, Vice President of the Hellenic Society of Cardiology

Konstantinidis Konstantinos

Vascular Surgeon, Thessaloniki, Greece

Koromboki Eleni

Curator of Internal Medicine, Department of Clinical Therapeutics, Alexandra General Hospital of Athens

Katsouras (Κατσούρας) Christos

Associate Professor of Cardiology, Faculty of Medicine, School of Health Sciences, University of Ioannina

Koulas Ioannis

MD, MSc Post Doctoral Research Trainee, Anticoagulation and Clinical Thrombosis Services, Institute of Health System Science Feinstein Institutes for Medical Research

Kozak Matija

MD, PhD, University Medical Centre Ljubljana, Department for Vascular Diseases, SLOVENIA

L

Lefkou Eleftheria

Curator Haematologist, Specialised in Haemostasis & Thrombosis, Obstetric Haematology, Antiphospholipid Syndrome

Liberopoulos Evangelos

Professor of Medicine-Metabolic Diseases, 1st Department of Propaedeutic Medicine, Medical School, National and Kapodistrian University of Athens

M

Milionis Haralampos

Professor of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Ioannina

Morais Joao (Portugal)

Cardiologist, Professor in Oporto Medical School, Head of the Cardiology Division Leiria Hospital Centre, Portugal

N

Nikas Dimitrios

MD, MSc, PhD, FESC, Interventional Cardiologist, Cardiology Department, University General Hospital of Ioannina, Greece

Nomikos Tzortzis

MSc, PhD, Associate Professor, Director of the Postgraduate Studies, School of Health Sciences and Education, Department of Nutrition and Dietetics Harokopio University

Nomikou Efrosyni

Hematologist, Director, National Health Care System of Blood Donation, Department of Haemophiliac, "Hippokration" General Hospital, Athens

Ntaios Georgios

MD, MSc (ESO Stroke Medicine), PhD, FESO, Associate Professor of Pathology, Faculty of Medicine, School of Health Sciences, University of Thessaly

P

Palaiodimou Lina

Neurologist, Second Department of Neurology, "Attikon"

Panagiotakos Demosthenes

Professor in Biostatistics, Research Methods and Epidemiology at Harokopio University in Athens, Greece

Papadopoulos Athanasios

Mayor of Kalavryta

Papadopoulos Vasileios

Associate professor ob-gyn, mfm, university of patras, member of hsmfm

Papanagiotou Panagiotis

Associate Professor of Radiology, National & Kapodistrian University of Athens, Professor of Neuroradiology, Bremen-Mitte Hospital, Germany

INDEX / INVITED FACULTY

Pappas Apostolos

Marketing Manager Cardiometabolics

Paschopoulos Minas

Professor of Obstetrics – Gynecology, Head of Obstetrics - Gynecology Clinic, Faculty of Medicine, School of Health Sciences, University of Ioannina, Vice Rector of the University of Ioannina

Pattakos Stratis

Director cardiac Surgery Hygeia Hospital

Pattakos Gregoris

Medical Doctor, MSc Student at Aristotle University of Thessaloniki (AUTH), Hellenic Air Force Officer

Pengo Vittorio

Professor of Cardiovascular Medicine (senior scientist), Thrombosis Research Laboratory, University of Padova, Bologna, Italy

Philippatos Theodosios

Assistant Professor of Internal Medicine, Metabolic Diseases Research Unit, Internal Medicine Laboratory, School of Medicine, University of Crete

Pipilis Athanasios

Cardiologist, Consultant, First Department of Cardiology, "Hygeia" Diagnostic and Therapeutic Centre of Athens

Protogerou Athanassios

MD, PhD, Professor of Pathological Physiology, Head of the Cardiovascular Prevention & Research Unit, Clinic & Laboratory of Pathophysiology, Department of Medicine, School of Health Sciences, National and Kapodistrian University of Athens

R

Richter Dimitrios

Cardiologist, Director of Cardiology Clinic, "Euroclinic" Athens

S

Sagris Dimitrios

Internist - Clinical Research Fellow, Department of Medicine and Research Laboratory, University of Thessaly, Larissa University Hospital

Savopoulos Christos

Professor of Internal Medicine, Director of 1st Medical Propedeutic Dept of Internal Medicine & Stroke Unit, Aristotle University of Thessaloniki, AHEPA University Hospital

Savvari Paraskevi

Senior Medical Manager, IM, Pfizer Hellas

Spanos Anastasios

MD, PhD, FESC, FSCAI, Rear Admiral - Cardiologist, Former Director of Cardiology Clinics, Navy Hospital of Athens, Director of Cardiology Department, Athens Medical Center & Euroclinic of Athens

Stefos Theodoros

Professor ob-gyn, mfm, university of ioannina, president of hsmfm

Spyropoulos Alex (USA)

Professor of Medicine, The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Professor - The Institute for Health Innovations and Outcomes Research - The Feinstein Institutes for Medical Research, System Director – Anticoagulation and Clinical Thrombosis Services, Northwell Health at Lenox Hill Hospital

T

Tentolouris Nikolaos

Professor of Medicine, 1st Department of Propaedeutic and Internal Medicine, Medical School, National and Kapodistrian University of Athens

INDEX / INVITED FACULTY

Tselepis Alexandros

Professor of Biochemistry - Clinical Chemistry, Department of Chemistry, University of Ioannina

Tsiara Stavroula

Associate Professor of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Ioannina

Tsoukalas Nikos

MD, MSc, PhD, Medical Oncologist, MSc Bioinformatics, Deputy Director, Oncology Department, 401 General Military Hospital Consultant, Henry Dunant Hospital Center, Athens Greece

Tsivgoulis Georgios

Professor of Neurology, School of Medicine, National & Kapodistrian University of Athens, Second Department of Neurology, Athens University General Hospital "ATTIKON"

Tzeis Stylianos

Head of Cardiology Department and Electrophysiology & Cardiac Pacing Section in Mitera Hospital, Hygeia Group

Tsiara Stavroula

Associate Professor of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Ioannina

Tzoulis Ploutarchos

MD, PhD, FRCP (Lon), MSc (Hons), CCT (UK) Hon. Associate Professor in Endocrinology, UCL (University College London) Medical School Consultant in Endocrinology, Diabetes & General Internal Medicine

V

Vardas Panos

Professor of Cardiology, University of Crete

Varon David

Hematology Blood and Marrow Transplant

Vemmos Konstantinos

Pathologist, Stroke Specialist, Hellenic Society of Cardiology

Ivor[®]
Bemiparin sodium

IvorMAX[®]
Bemiparin sodium



ΣΥΝΟΠΤΙΚΗ ΠΕΡΙΓΡΑΦΗ ΤΩΝ ΧΑΡΑΚΤΗΡΙΣΤΙΚΩΝ ΤΟΥ ΠΡΟΪΟΝΤΟΣ

ΟΝΟΜΑΣΙΑ ΤΟΥ ΦΑΡΜΑΚΕΥΤΙΚΟΥ ΠΡΟΪΟΝΤΟΣ: Ivor 2.500 IU anti-Xa/0,2 ml ενέσιμου διαλύματος σε προγεμισμένες σύριγγες. **ΠΟΙΟΤΙΚΗ & ΠΟΣΟΤΙΚΗ ΣΥΝΘΕΣΗ:** Bemiparin sodium: 2.500 IU (anti Factor Xa*) ανά 0,2 ml προγεμισμένη σύριγγα (ισοδύναμη με 12.500 IU (anti Factor Xa*) ανά ml ενέσιμου διαλύματος). Η δραστηριότητα περιγράφεται σε Διεθνείς μονάδες anti-Factor Xa δραστηριότητας (IU) με βάση το Πρώτο Διεθνές Πρότυπο Αναφοράς Ηπαρίνης Χαμηλού Μοριακού Βάρους. Για τον πλήρη κατάλογο των εκδόχων, βλ. παράγραφο 6.1.

ΣΥΣΚΕΥΑΣΙΕΣ/ΤΙΜΕΣ: IVOR 2.500 IU anti-Xa/0,2 ml BT x 2 PF.SYR A.T.: 5,83 €

ΟΝΟΜΑΣΙΑ ΤΟΥ ΦΑΡΜΑΚΕΥΤΙΚΟΥ ΠΡΟΪΟΝΤΟΣ: Ivormax 25.000 IU anti-Xa/ml ενέσιμου διαλύματος σε προγεμισμένες σύριγγες. **ΠΟΙΟΤΙΚΗ & ΠΟΣΟΤΙΚΗ ΣΥΝΘΕΣΗ:** Bemiparin sodium: 3.500 IU (anti Factor Xa*) ανά 0,2 ml προγεμισμένη σύριγγα (ισοδύναμη με 17.500 IU (anti Factor Xa*) ανά ml ενέσιμου διαλύματος). Η δραστηριότητα περιγράφεται σε Διεθνείς μονάδες anti-Factor Xa δραστηριότητας (IU) με βάση το Πρώτο Διεθνές Πρότυπο Αναφοράς Ηπαρίνης Χαμηλού Μοριακού Βάρους. Για τον πλήρη κατάλογο των εκδόχων, βλ. παράγραφο 6.1.

ΣΥΣΚΕΥΑΣΙΕΣ/ΤΙΜΕΣ: IVOR 3.500 IU anti-Xa/0,2 ml BT x 2 PF.SYR A.T.: 10,74 € BT x 30 PF.SYR A.T.: 120,83 €

ΟΝΟΜΑΣΙΑ ΤΟΥ ΦΑΡΜΑΚΕΥΤΙΚΟΥ ΠΡΟΪΟΝΤΟΣ: Ivormax 25.000 IU anti-Xa/ml ενέσιμου διαλύματος σε προγεμισμένες σύριγγες. **ΠΟΙΟΤΙΚΗ & ΠΟΣΟΤΙΚΗ ΣΥΝΘΕΣΗ:** Bemiparin sodium: 25.000 IU (anti-Factor Xa*) ανά ml ενέσιμου διαλύματος. Ισοδύναμη με: 5.000 IU (anti-Factor Xa) ανά 0,2 ml προγεμισμένη σύριγγα, 7.500 IU (anti-Factor Xa) ανά 0,3 ml προγεμισμένη σύριγγα, 10.000 IU (anti-Factor Xa) ανά 0,4 ml προγεμισμένη σύριγγα. * Η δραστηριότητα περιγράφεται σε Διεθνείς μονάδες anti-Factor Xa δραστηριότητας (IU) με βάση το Πρώτο Διεθνές Πρότυπο Αναφοράς Ηπαρίνης Χαμηλού Μοριακού Βάρους. Για τον πλήρη κατάλογο των εκδόχων, βλ. παράγραφο 6.1. **ΣΥΣΚΕΥΑΣΙΕΣ/ΤΙΜΕΣ:** IVORMAX 25.000 IU anti-Xa/ml, BTx2PF.SYRx0,2ML A.T.: 21,86€, IVORMAX 25.000 IU anti-Xa/ml, BTx2PF.SYRx0,3ML A.T.: 19,09€, IVORMAX 25.000 IU anti-Xa/ml BTx2PF.SYRx0,4ML A.T.: 23,33€

ΦΑΡΜΑΚΟΤΕΧΝΙΚΗ ΜΟΡΦΗ: Ενέσιμο διάλυμα σε προγεμισμένες σύριγγες. (Άχρωμο ή ελαφρώς κίτρινωπό, διαυγές διάλυμα, ελεύθερο ορατών σωματιδίων). **ΚΑΤΟΧΟΣ ΑΔΕΙΑΣ ΚΥΚΛΟΦΟΡΙΑΣ:** BIANEΞ Α.Ε. – Οδός Τατοΐου, 146 71 Νέα Ερυθραία, Τηλ. 210 8009111.

ΗΜΕΡΟΜΗΝΙΑ ΑΝΑΘΕΩΡΗΣΗΣ ΤΟΥ ΚΕΙΜΕΝΟΥ: 12-10-2021

ΤΡΟΠΟΣ ΔΙΑΘΕΣΗΣ: Φαρμακευτικό προϊόν για το οποίο απαιτείται ιατρική συνταγή
Περαιτέρω πληροφορίες διατίθενται από τον ΚΑΚ κατόπιν αιτήσεως.



BIANEΞ A.E.
ΒΙΟΜΗΧΑΝΙΑ ΦΑΡΜΑΚΩΝ
ΕΤΑΙΡΕΙΑ ΤΟΥ ΟΜΙΛΟΥ ΓΙΑΝΝΑΚΟΠΟΥΛΟΥ

BIANEΞ Α.Ε. – Έδρα : οδός Τατοΐου, 18^ο χλμ. Ε.Ο. Αθηνών – Λαμίας 146 71 Ν. Ερυθραία Αττικής, Ταχ. Θυρίδα 52894, 146 10 Ν. Ερυθραία
Τηλ. : 210 8009111 • Fax: 210 8071573 • E-mail: mailbox@vianex.gr • WEBSITE: www.vianex.gr
ΘΕΣΣΑΛΟΝΙΚΗ: Ακαδημίου 113, 562 24 Εύοσμος Θεσσαλονίκης Τηλ.: 2310 861683

ΑΡ. Γ.Ε.ΜΗ. 000274201000

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και
Αναφέρετε
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για
ΟΛΑ τα φάρμακα
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»



VE-22096-IVO-4/2022



Liptruzet®

(ezetimibe and atorvastatin) tablets

Ο **μόνος*** σταθερός συνδυασμός
εξετιμίμης/ατορβαστατίνης
με εγκεκριμένη ένδειξη
στη **Πρόληψη των Καρδιαγγειακών Επεισοδίων¹**

4. ΚΛΙΝΙΚΕΣ ΠΛΗΡΟΦΟΡΙΕΣ

4.1 Θεραπευτικές ενδείξεις

Πρόληψη των Καρδιαγγειακών Επεισοδίων

Το LIPTRUZET ενδείκνυται για τη μείωση του κινδύνου των καρδιαγγειακών επεισοδίων (βλ. παράγραφο 5.1) σε ασθενείς με στεφανιαία νόσο (ΣΝ) και με ιστορικό οξέος στεφανιαίου συνδρόμου (ΟΣΣ), που είτε έχουν λάβει προηγούμενη θεραπεία με στατίνη είτε όχι.

1. ΠΧΠ LIPTRUZET_31_08_2021

* Σύμφωνα με τις ΠΧΠ των κυκλοφορούντων σταθερών συνδυασμών εξετιμίμης/ατορβαστατίνης στην Ελλάδα

Πριν τη συνταγογράφηση συμβουλευτείτε την περιληψη χαρακτηριστικών του προϊόντος.

LIPTRUZET® (10+10) MG/TAB | ΛΤ: 42,81€,
LIPTRUZET® (10+20) MG/TAB | ΛΤ: 40,92€,
LIPTRUZET® (10+40) MG/TAB | ΛΤ: 40,56€.



BIANEX A.E.
ΒΙΟΜΗΧΑΝΙΑ ΦΑΡΜΑΚΩΝ
ΕΤΑΙΡΕΙΑ ΤΟΥ ΟΜΙΛΟΥ ΓΙΑΝΝΑΚΟΠΟΥΛΟΥ

Τοπικός Αντιπρόσωπος:
BIANEX A.E. - Έδρα : οδός Τατοίου, 18^ο χλμ. Ε.Ο. Αθηνών – Λαμίας ,
146 71 Ν. Ερυθραία Αττικής, Ταχ. Θυρίδα 52894, 146 10 Ν. Ερυθραία,
Τηλ.: 210 8009111 • Fax: 210 8071573
E-mail: mailbox@vianex.gr • WEBSITE: www.vianex.gr
ΘΕΣΣΑΛΟΝΙΚΗ: Ακαδημίου 113, 562 24 Εύοσμος Θεσσαλονίκης, Τηλ.: 2310 861683
ΑΡ. Γ.Ε.ΜΗ. 000274201000

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και
αυτοφύρετα
ΟΛΕΣ τις ανακυκλώσιμες συσκευασίες για
όλα τα φάρμακα
Συμμετέχοντας στην «ΕΠΙΤΡΩΗ ΚΑΡΤΑ»

 **ORGANON**

Κάτοχος Άδειας Κυκλοφορίας :
N.V. Organon, Kloosterstraat 6,
5349 AB Oss,
Ολλανδία.

GENERAL INFORMATION

■ DATE & VENUE

The **Advanced Learning on Platelets and Thrombosis International Course (ALPIC 2022)** is held from **Friday, November 4th to Sunday, November 6th 2022** in Kalavrita, Greece, at Kalavrita Canyon Hotel.

The **ALPIC 2022** will be realized in Kalavrita Canyon Hotel, a 4* hotel situated in **Kalavrita**, Achaia region of Peloponnese, Greece. In the heart of the beautiful and historic town of Kalavrita, **ALPIC 2022** will be actualized in the hotel's Conference Halls. The Conference will be conducted in a hybrid manner (with physical presence of a number of participants and simultaneous on Digital Broadcast). In case, for epidemiological reasons, the conference cannot be held with physical presence, it will be held entirely online.

■ ABOUT KALAVRITA

Kalavrita is a town in the mountainous east-central part of the regional unit of Achaia in Peloponnese, Greece. The town is located 24 kilometres south of Aigio and 40 km southeast of Patras. Kalavrita is surrounded by beautiful mountains Erymanthos in the west and Chelmos in the southeast.

Kalavrita area brings together a large number of attractions of historical and religious significance and natural beauty. The Vouraikos Canyon is among the Global Network of Geoparks, which was established under the auspices of UNESCO, and a geological monument of world heritage. This natural richness of the Greek geological heritage can be admired in a magical journey with **the cog of Kalavrita**. The **Cave of the Lakes** is also a work of nature worth to visit just minutes away from the town of Kalavryta. In the **Monastery of the Great Cave** you can admire one of the four projects of the Evangelist Luke, the embossed image of the Virgin Chrysospiliotissa while **Holy Agia Lavra Monastery** holds the first place as a national-religious pilgrimage and is a unique historical monument. The **Museum of the Holocaust** the historic Elementary school which houses the history and the memory of the 1943 drama in Kalavrita. The **Place of Sacrifice** is located a few meters outside the city, the sacred place where the massacre of Kalavryta took place. The destination of Kalavryta is ideal for those who love nature and sports suitable for all seasons. The activities vary according to your desire and mood. During winter time, snow lovers have the opportunity to enjoy **the snowy ski resort** to take a walk or indulge in their favorite activities such as ski, snowboard, ski mobiles. During the other seasons of the year however, the proposed activities are numerous.

A large number of trails of all difficulty levels, suitable for **Hiking and Mountaineering**, that all have something in common: the opportunity to admire the unique beauty of the Greek nature. These images of nature can also be admired by anyone engaged in sports in the river **Ladon kayaking or rafting**. A few adventurous have the opportunity to gaze nature from above by **paragliding**.

For those seeking the coolness combined with trips to the beach during the summer, Kalavrita is a destination located just 30 minutes away from two **beaches** with crystal-clear waters.

■ LANGUAGE

The official languages of the Course are **Greek** and **English**. The English language may be used widely especially in the presentations of the speakers to encourage the interaction in all scientific sessions of the English speaking faculty.

■ REGISTRATIONS

Registration Fee: 200.00 euros + 24% VAT

Registration Fee includes:

- Access to Conference & exhibition area
- Conference material (e-program & e-badge & codes for digital access)
- e-Certificate of attendance
- Attendance at the organized Coffee breaks during the Scientific Program

Digital Registration Fee: 50.00 euros + 24% VAT

Digital Registration Fee includes:

- Access to digital Conference
- Conference material (e-program & codes for digital access)
- e-Certificate of attendance

■ CREDITS

The Congress will be accredited with 21 C.M.E. Credits by the Panhellenic Medical Association.

■ CERTIFICATE OF ATTENDANCE

Continuing Medical Education Credits will be awarded by the Panhellenic Medical Association. All registered to the Course will have their e-badge and codes (username and password) for digital access that will count the time of attendance (physically or virtually). Each (1) credit of Continuing Medical Education corresponds to one full hour attendance. Participants can download their Certificates 2 dates after the end of the Course from the site of Congress World <https://certificates.congressworld.gr/gr/congress>.

■ CONTACT



Congress World

27, Michalakopoulou Ave, 115 28, Athens Greece
Tel: +30 (210) 7210001, 7210052, 7222518, 7210025
E-mail: info@congressworld.gr, ea@congressworld.gr
www.congressworld.gr

SPONSORS

The Organizers wish to thank the following pharmaceutical companies for their support in the accomplishment of the Course:



Bayer



BIANEE A.E.
ΒΙΟΜΗΧΑΝΙΑ ΦΑΡΜΑΚΩΝ
ΕΤΑΙΡΕΙΑ ΤΟΥ ΟΜΙΛΟΥ ΓΙΑΝΝΑΚΟΠΟΥΛΟΥ



**Boehringer
Ingelheim**



VIATRIS



Pharmaceutical Laboratories S.A.



PP-XAR-GR-0461-1
02.2022



Bayer

Κάτοχος της άδειας κυκλοφορίας:
Bayer AG, 51368 Leverkusen, Γερμανία.
Τοπικός αντιπρόσωπος του κατόχου αδείας
κυκλοφορίας στην Ελλάδα: Bayer Ελλάς
ABEE, Σωρού 18-20, 151 25 Μαρούσι.
Τοπικός αντιπρόσωπος του κατόχου αδείας
κυκλοφορίας στην Κύπρο: Novagem Ltd,
Τηλ: 00357 22483858.

Τμήμα Επιστημονικής Ενημέρωσης
Τηλ: +30 210 6187742, Fax: +30 210 6187522
Email: medinfo.gr.cy@bayer.com

Εταιρεία συμπτώθησης



ELPEN Α.Ε. ΦΑΡΜΑΚΕΥΤΙΚΗ ΒΙΟΜΗΧΑΝΙΑ
Λεωφ. Μαραθώνος 95, 190 09 Πικέρμι Αττικής,
Τηλ: 210 6039326 - 9, Fax: 210 6039300
ΓΡΑΦΕΙΑ ΕΠΙΣΤΗΜΟΝΙΚΗΣ ΕΝΗΜΕΡΩΣΗΣ
Σεβαστείας 11, 115 28 Αθήνα,
Τηλ: 210 7488711, Fax: 210 7488731
Εθν. Αντιστάσεως 114, 551 34 Θεσσαλονίκη,
Τηλ: 2310 459920 - 1, Fax: 2310 459269



Xarelto®

rivaroxaban

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και
Αναφέρετε
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για
ΟΛΑ τα φάρμακα
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»